TheStreet cut shares of CryoLife, Inc. (NYSE:CRY) from a b rating to a c+ rating in a report published on Monday.

A number of other analysts have also issued reports on the company. Lake Street Capital increased their target price on CryoLife to $26.00 and gave the company a buy rating in a report on Wednesday, October 11th. Zacks Investment Research lowered CryoLife from a hold rating to a sell rating in a report on Tuesday, October 17th. BidaskClub lowered CryoLife from a buy rating to a hold rating in a report on Monday, July 24th. Finally, Canaccord Genuity reiterated a buy rating and set a $25.00 price objective on shares of CryoLife in a report on Monday, October 9th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of $23.63.

CryoLife (NYSE:CRY) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.08. The company had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.13 earnings per share.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/cryolife-inc-cry-stock-rating-lowered-by-thestreet/1674456.html.

In related news, Director James Benson sold 2,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total transaction of $45,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James P. Mackin sold 43,050 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total value of $950,974.50. Following the sale, the chief executive officer now owns 398,399 shares of the company’s stock, valued at $8,800,633.91. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 171,050 shares of company stock valued at $3,769,825. 6.00% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its position in CryoLife by 16.5% during the first quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock worth $517,000 after buying an additional 4,399 shares during the last quarter. Royce & Associates LP increased its position in CryoLife by 10.0% during the second quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock worth $8,682,000 after buying an additional 39,500 shares during the last quarter. Ameriprise Financial Inc. increased its position in CryoLife by 4.6% during the first quarter. Ameriprise Financial Inc. now owns 162,996 shares of the medical equipment provider’s stock worth $2,714,000 after buying an additional 7,228 shares during the last quarter. William Blair Investment Management LLC acquired a new position in CryoLife during the second quarter worth $4,517,000. Finally, Marshall Wace North America L.P. increased its position in CryoLife by 118.4% during the second quarter. Marshall Wace North America L.P. now owns 133,021 shares of the medical equipment provider’s stock worth $2,660,000 after buying an additional 72,114 shares during the last quarter. 69.01% of the stock is currently owned by hedge funds and other institutional investors.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.